Preoperative Gadoxetic Acid-Enhanced MRI Based Nomogram Improves Prediction of Early HCC Recurrence After Ablation Therapy.
Preoperative Gadoxetic Acid-Enhanced MRI Based Nomogram Improves Prediction of Early HCC Recurrence After Ablation Therapy.
复制标题
术前基于钆塞酸增强 MRI 的列线图可改善消融治疗后早期 HCC 复发的预测
DOI：
10.3389/fonc.2021.649682
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Zhou Y
中科院分区：
文献类型：
--
作者：
Hu C;Song Y;Zhang J;Dai L;Tang C;Li M;Liao W;Zhou Y;Xu Y;Zhang YY;Zhou Y
This study aimed to identify preoperative gadoxetic acid-enhanced MRI features and establish a nomogram for predicting early recurrence (≤ 2 years) of hepatocellular carcinoma (HCC) after ablation therapy. A total of 160 patients who underwent gadoxetic acid-enhanced MRI and ablation HCC therapy from January 2015 to June 2018, were included retrospectively and divided into a training cohort (n = 112) and a validation cohort (n = 48). Independent clinical risk factors and gadoxetic acid-enhanced MRI features associated with early recurrence were identified by univariate and multivariate logistic regression analysis and used for construction of a nomogram. The performance of the nomogram was evaluated by discrimination, calibration, and clinical utility. Alpha-fetoprotein (AFP) level, tumor number, arterial peritumoral enhancement, satellite nodule and peritumoral hypointensity at hepatobiliary phases in the training cohort were identified as independent risk factors for early recurrence after ablation. A new nomogram that was constructed with these five features showed an area under the curve (AUC) of 0.843 (95%CI 0.771-0.916) and 0.835 (95%CI 0.713-0.956) in the training and validation cohort, respectively. The calibration curve and decision curve analysis (DCA) suggested that the nomogram had good consistency and clinical utility. A new nomogram that was constructed using four preoperative gadoxetic acid-enhanced MRI features and serum AFP level can predict the risk of early HCC recurrence after ablation therapy with AUC up to 0.843. The strong performance of this nomogram may help hepatologists to categorize patients’ recurrent risk to guide selecting treatment options and improve postoperative management.
登录
查看更多内容
影响因子：
29.4
作者：
Roayaie S;Blume IN;Thung SN;Guido M;Fiel MI;Hiotis S;Labow DM;Llovet JM;Schwartz ME
通讯作者：
Schwartz ME
影响因子：
4
作者：
An, Chao;Wu, Songsong;Huang, Jinhua
通讯作者：
Huang, Jinhua
影响因子：
28.4
作者：
Global Burden of Disease Cancer Collaboration;Fitzmaurice C;Allen C;Barber RM;Barregard L;Bhutta ZA;Brenner H;Dicker DJ;Chimed-Orchir O;Dandona R;Dandona L;Fleming T;Forouzanfar MH;Hancock J;Hay RJ;Hunter-Merrill R;Huynh C;Hosgood HD;Johnson CO;Jonas JB;Khubchandani J;Kumar GA;Kutz M;Lan Q;Larson HJ;Liang X;Lim SS;Lopez AD;MacIntyre MF;Marczak L;Marquez N;Mokdad AH;Pinho C;Pourmalek F;Salomon JA;Sanabria JR;Sandar L;Sartorius B;Schwartz SM;Shackelford KA;Shibuya K;Stanaway J;Steiner C;Sun J;Takahashi K;Vollset SE;Vos T;Wagner JA;Wang H;Westerman R;Zeeb H;Zoeckler L;Abd-Allah F;Ahmed MB;Alabed S;Alam NK;Aldhahri SF;Alem G;Alemayohu MA;Ali R;Al-Raddadi R;Amare A;Amoako Y;Artaman A;Asayesh H;Atnafu N;Awasthi A;Saleem HB;Barac A;Bedi N;Bensenor I;Berhane A;Bernabé E;Betsu B;Binagwaho A;Boneya D;Campos-Nonato I;Castañeda-Orjuela C;Catalá-López F;Chiang P;Chibueze C;Chitheer A;Choi JY;Cowie B;Damtew S;das Neves J;Dey S;Dharmaratne S;Dhillon P;Ding E;Driscoll T;Ekwueme D;Endries AY;Farvid M;Farzadfar F;Fernandes J;Fischer F;G/Hiwot TT;Gebru A;Gopalani S;Hailu A;Horino M;Horita N;Husseini A;Huybrechts I;Inoue M;Islami F;Jakovljevic M;James S;Javanbakht M;Jee SH;Kasaeian A;Kedir MS;Khader YS;Khang YH;Kim D;Leigh J;Linn S;Lunevicius R;El Razek HMA;Malekzadeh R;Malta DC;Marcenes W;Markos D;Melaku YA;Meles KG;Mendoza W;Mengiste DT;Meretoja TJ;Miller TR;Mohammad KA;Mohammadi A;Mohammed S;Moradi-Lakeh M;Nagel G;Nand D;Le Nguyen Q;Nolte S;Ogbo FA;Oladimeji KE;Oren E;Pa M;Park EK;Pereira DM;Plass D;Qorbani M;Radfar A;Rafay A;Rahman M;Rana SM;Søreide K;Satpathy M;Sawhney M;Sepanlou SG;Shaikh MA;She J;Shiue I;Shore HR;Shrime MG;So S;Soneji S;Stathopoulou V;Stroumpoulis K;Sufiyan MB;Sykes BL;Tabarés-Seisdedos R;Tadese F;Tedla BA;Tessema GA;Thakur JS;Tran BX;Ukwaja KN;Uzochukwu BSC;Vlassov VV;Weiderpass E;Wubshet Terefe M;Yebyo HG;Yimam HH;Yonemoto N;Younis MZ;Yu C;Zaidi Z;Zaki MES;Zenebe ZM;Murray CJL;Naghavi M
通讯作者：
Naghavi M
DOI：
10.1016/s1470-2045(14)71116-7
发表时间：
2015-04
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Balachandran VP;Gonen M;Smith JJ;DeMatteo RP
通讯作者：
DeMatteo RP
影响因子：
25.7
作者：
Lee, Dong Ho;Lee, Jeong Min;Choi, Byung Ihn
通讯作者：
Choi, Byung Ihn